Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
  • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
  • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
  • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
  • C07D451/06—Oxygen atoms
  • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Definitions

• the invention relates to novel thienylcarboxylates of amino alcohols and their quaternary products and to the preparation of the novel compounds and their use as active ingredients in medicaments.
• R 1 preferably represents thienyl
• R 2 preferably represents OH
• the group —OA preferably has the ⁇ -configuration and is derived from, for example scopine, tropine, granatoline or 6,7-dehydrotropine or the corresponding nor-compounds; however, —OA may also have the ⁇ -configuration, as in pseudotropine, pseudoscopine.
• the substituent R is preferably a lower alkyl radical, such as CH 3 , C 2 H 5 , n-C 3 H 7 , i-C 3 H 7 , R′ is preferably CH 3 .
• R and R′ together are, for example —(CH 2 ) 5 —.
• halogen substituents for R F or, as second choice, Cl are suitable.
• R denotes a halogen-substituted or hydroxy-substituted alkyl radical, it is preferably —CH 2 —CH 2 F or —CH 2 —CH 2 OH.
• the group A represents, for example the radicals of scopine, N-ethylnorscopine, N-isopropylnorscopine, tropine, N-isopropylnortropine, 6,7-dehydrotropine, N- ⁇ -fluoroethylnortropine, N-isopropyl-6,7-dehydronortropine, N-methylgranatoline or the corresponding quaternary compounds, wherein the anion is preferably Br ⁇ or CH 3 SO 3 ⁇ .
• the quaternary compounds are particularly suitable for therapeutic application, whereas the tertiary compounds are important not only as active ingredients but also as intermediate products.
• the compounds of the invention are strong anti-cholinergic agents and have prolonged action. Action lasting at least 24 hours is achieved at inhaled dosages in the ⁇ g range. In addition, the toxicity is in the same range as the commercial product Ipratropium bromide, while at the same time the therapeutic effect is stronger.
• novel compounds are suitable, in accordance with their anti-cholinergic nature, for example for the treatment of chronic obstructive bronchitis and (slight to moderately severe) asthma, also for the treatment of vagally induced sinus bradycardia.
• the novel active ingredients in particular the quaternary compounds
• the application for sinus bradycardia is preferably carried out intravenously or orally. It has thus proved to be advantageous that the novel compounds leave the gastro/intestinal motility largely unaffected.
• the compounds of the invention are processed using known auxiliaries and/or excipients to give conventional galenic preparations, for example inhalation solutions, suspensions in liquified propellants, preparations containing liposomes or proliposomes, injection solutions, tablets, coated tablets, capsules, inhalation powders for use in conventional inhalation apparatus.
• conventional galenic preparations for example inhalation solutions, suspensions in liquified propellants, preparations containing liposomes or proliposomes, injection solutions, tablets, coated tablets, capsules, inhalation powders for use in conventional inhalation apparatus.
• Controlled dosage aerosol Active ingredient 0.005 Sorbitan trioleate 0.1 monofluorotrichloromethane and to 100 Difluorodichloromethane 2:3
• the suspension is poured into a conventional aerosol container with a dosage valve. 50 ⁇ l of suspension are preferably dispensed per actuation.
• the active ingredient may also be metered in a higher amount if required (for example 0.02 wt. %).
• Tablets Active ingredient according to the invention 0.05 Colloidal silicic acid 0.95 Lactose 65.00 Potato starch 28.00 Polyvinylpyrrolidone 3.00 Na cellulose glycolate 2.00 Magnesium stearate 1.00 The constituents are processed in conventional manner to give tablets of 200 mg.
• the advantageous properties of the novel compounds are shown, for example, in the inhibition of broncholysis in the rabbit (acetylcholine spasms intravenously).
• the maximum effect occurred after 10 to 40 minutes.
• the inhibiting effect had still not been reduced to half, that is to say the half effect time is more, in some cases considerably more, than 5 hours, as made clear by the residual effects after 5 hours listed below:
• R′′ represents a C 1 -C 4 -alkyl radical, preferably a methyl or ethyl radical (R 1 , R 2 and R a have the above meanings)
• R 1 , R 2 and R a have the above meanings
• R 1 , R 2 and R a have the above meanings
• Q′′ represents ⁇ NR or ⁇ NH and the OH group is in the ⁇ - or ⁇ -position, in the presence of a conventional transesterification catalyst, and the compound obtained is optionally quaternised
• the transesterification is carried out with heat in an organic solvent, for example toluene, xylene, heptane, or in a melt, strong bases such as sodium methylate, sodium ethylate, sodium hydride, metallic sodium, being used as catalyst. Reduced pressure is used to remove the released lower alcohol from the equilibrium, the alcohol is optionally distilled off azeotropically.
• the transesterification takes place at temperatures which in general do not exceed 95° C. Transesterification often proceeds more favourably in a melt.
• the free bases may be obtained in a manner known per se from acid addition salts of the tertiary amines using suitable basic compounds.
• Quaternisation is carried out in suitable solvents, for example acetonitrile or acetonitrile/methylene chloride, preferably at room temperature; a corresponding alkyl halide, for example alkyl bromide, is preferably used in the process as quaternising agent.
• suitable solvents for example acetonitrile or acetonitrile/methylene chloride, preferably at room temperature; a corresponding alkyl halide, for example alkyl bromide, is preferably used in the process as quaternising agent.
• Transesterification products wherein Q′ represents NH are used as starting materials for those compounds in which R and R′ together represent a C 4 -C 6 -alkylene group. Conversion into the tertiary and then quaternary compound then takes place with the aid of suitable 1,4-dihaloalkanes, 1,5-dihaloalkanes or 1,6-dihaloalkanes without isolation of intermediates.
• the starting materials may be obtained analogously to known compounds—in as much as they have not already been described.
• Pseudoscopine may be obtained in accordance with M. Polonovski et al., Bull. soc. chim. 43, 79 (1928). Pseudotropenol may be removed from the mixture, (fractional crystallisation or distillation) which is obtained, for example in accordance with V. Hayakawa et al., J. Amer. Chem. Soc. 1978, 100(6), 1786 or R. Noyori et al., J. Amer. Chem. Soc. 1974, 96(10), 3336.
• the corresponding methyl esters may be prepared in a conventional manner starting from 2-furylglyoxylnitrile or 3-furylglyoxylnitrile via the 2-furylglyoxylic acid or 3-furylglyoxylic acid which can be obtained therefrom.
• the corresponding glycolates are obtained from these as described using the organometallic derivatives of 2-bromothiophene or 3-bromothiophene.
• the organometallic compounds which can be obtained from 2-, 3- or 4-halopyridine can be reacted with methyl 2-thienylglyoxylate or methyl 3-thienylglyoxylate to give the corresponding glycolates.
• Thienylglycolates in which the thiophene ring contains fluorine in the 2- or 3-position, are prepared, for example starting from 2-fluorothiophene or 3-fluorothiophene (bromination to give 2-bromo-3-fluorothiophene or 2-bromo-5-fluorothiophene), and after conversion to the corresponding organometallic compounds, reaction with suitable glyoxylates to give the glycolates.
• 2-Fluorothiophene and 3-fluorothiophene can be reacted analogously to give the corresponding glyoxylates Unterhalt, Arch. Pharm. 322, 839 (1989) which in turn, as already described, may be reacted with, for example 2-thienyl or 3-thienyl derivatives, to give glycolates.
• Symmetrically substituted di-thienylglycolates can be prepared analogously by selecting suitable components.
• a further route is available via a process analogous to the benzoin condensation and benzilic acid rearrangement.
• the scopine di-(2-thienyl)glycolate is extracted from the combined aqueous phases using methylene chloride after adding the corresponding amount of sodium carbonate and dried over sodium sulphate.
• the hydrochloride is prepared from the dried methylene chloride solution in a conventional manner. The crystals are filtered off under suction, washed using acetone and dried under reduced pressure at 35° C. Pale yellow crystals (from methanol), m.p. 238°-41° C. (decomposition);
• the hydrochloride may be converted to the base in a conventional manner.
• the hydrochloride of the basic ester crystallising out is filtered off under suction and washed using a small amount of water and a large amount of diethyl ether.
• the filtrate phases are separated off and the aqueous phase is extracted using diethyl ether.
• the hydrochloride filtered off under suction is suspended in the (acid) aqueous phase and converted to the base while monitoring the temperature and adding the corresponding amount of sodium carbonate; the base is extracted using methylene chloride.
• the combined methylene chloride phases are dried over sodium sulphate. After distilling off the methylene chloride, crystals remain which are purified over active charcoal and recrystallised from acetonitrile. Pale yellow crystals (from acetonitrile), m.p. 148°-49° C.;

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Pulmonology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Cardiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Glass Compositions (AREA)
• Compositions Of Oxide Ceramics (AREA)
• Disintegrating Or Milling (AREA)

Priority Applications (1)

Applications Claiming Priority (9)

Related Parent Applications (1)

Publications (1)

Family

ID=6389619

Family Applications (1)

Country Status (33)

Cited By (33)

Families Citing this family (116)

Citations (9)

• 1989
  • 1989-09-16 DE DE3931041A patent/DE3931041C2/de not_active Expired - Lifetime
• 1990
  • 1990-09-06 DD DD90343854A patent/DD297647A5/de not_active IP Right Cessation
  • 1990-09-08 RU SU905011520A patent/RU2073677C1/ru active
  • 1990-09-08 AU AU64318/90A patent/AU642913B2/en not_active Expired
  • 1990-09-08 HU HU9200857A patent/HU208823B/hu unknown
  • 1990-09-08 UA UA93060616A patent/UA41272C2/uk unknown
  • 1990-09-08 WO PCT/EP1990/001517 patent/WO1991004252A1/de active IP Right Grant
  • 1990-09-08 JP JP2513253A patent/JPH0730074B2/ja not_active Expired - Lifetime
  • 1990-09-08 CA CA002066248A patent/CA2066248C/en not_active Expired - Lifetime
  • 1990-09-12 DK DK90117554.7T patent/DK0418716T3/da active
  • 1990-09-12 DE DE90117554T patent/DE59005250D1/de not_active Expired - Lifetime
  • 1990-09-12 DE DE2002199026 patent/DE10299026I2/de active Active
  • 1990-09-12 EP EP90117554A patent/EP0418716B1/de not_active Expired - Lifetime
  • 1990-09-12 AT AT90117554T patent/ATE103914T1/de active
  • 1990-09-12 ES ES90117554T patent/ES2052125T3/es not_active Expired - Lifetime
  • 1990-09-13 YU YU174490A patent/YU47800B/sh unknown
  • 1990-09-13 SI SI9011744A patent/SI9011744B/sl unknown
  • 1990-09-14 KR KR1019900014543A patent/KR0168432B1/ko not_active IP Right Cessation
  • 1990-09-14 ZA ZA907338A patent/ZA907338B/xx unknown
  • 1990-09-14 PH PH41212A patent/PH31617A/en unknown
  • 1990-09-14 PT PT95312A patent/PT95312B/pt not_active IP Right Cessation
  • 1990-09-14 NZ NZ235306A patent/NZ235306A/en unknown
  • 1990-09-14 IL IL9569190A patent/IL95691A/en active Protection Beyond IP Right Term
  • 1990-09-17 CZ CS904523A patent/CZ284589B6/cs not_active IP Right Cessation
  • 1990-09-17 SK SK4523-90A patent/SK279453B6/sk not_active IP Right Cessation
• 1992
  • 1992-03-13 NO NO921002A patent/NO301478B1/no not_active IP Right Cessation
  • 1992-03-13 IE IE334290A patent/IE65528B1/en active Protection Beyond IP Right Term
  • 1992-03-13 FI FI921087A patent/FI114395B/fi active Protection Beyond IP Right Term
  • 1992-03-13 PL PL90286900A patent/PL168468B1/pl active Protection Beyond IP Right Term
  • 1992-06-23 MX MX9203150A patent/MX9203150A/es unknown
• 1994
  • 1994-02-23 BG BG98532A patent/BG61295B2/bg unknown
  • 1994-10-21 HR HRP-1744/90A patent/HRP940723B1/xx not_active IP Right Cessation
  • 1994-12-15 HU HU94P/P00055P patent/HU210612A9/hu unknown
• 2002
  • 2002-02-14 NL NL300084C patent/NL300084I2/nl unknown
  • 2002-08-30 LU LU90949C patent/LU90949I2/fr unknown
  • 2002-09-17 NO NO2002009C patent/NO2002009I2/no unknown
• 2005
  • 2005-10-18 US US11/254,213 patent/USRE39820E1/en not_active Expired - Lifetime

Patent Citations (9)

Non-Patent Citations (29)

Also Published As

Similar Documents

Legal Events